A REVIEW: ALCOHOLIC HEPATITIS, PROGNOSTIC INDICATORS AND THERAPEUTIC OUTCOMES.

AUTHORS: *Mrs. K. Sivaranjani, S. Logeshwari[2], D. Madhumitha[3], S. Delsiya[4], P. Gopi Arun[5] , Dr M. Rajesh[6.]

1. Assistant Professor, Department of Pharmaceutics.
2 to 5. 7th semester B. Pharm
6. Head & Professor, Department of Pharmaceutics
Sankaralingam Bhuvaneshwari College of Pharmacy
(Affiliated to The TN. Dr M.G.R. Medical University -Chennai)

Abstract: *Alcoholic Hepatitis (AH) is a severe inflammatory condition of the liver triggered by excessive alcohol consumption, often superimposed on chronic liver disease. It presents with a spectrum of clinical manifestations ranging from mild hepatic dysfunction to life-threatening liver failure. Prognostic indicators, such as the Maddrey Discriminant Function (mDF), Model for End-Stage Liver Disease (MELD), Lille score, and Glasgow Alcoholic Hepatitis Score (GAHS), are crucial in stratifying disease severity and informing therapeutic decisions. Despite corticosteroids being the mainstay of treatment for severe AH, their efficacy remains limited, and alternative therapies like pentoxifylline and N-acetylcysteine have shown mixed results. Liver transplantation is a viable option for select non-responders. This review evaluates the utility of prognostic models and summarises current and emerging therapeutic strategies*

Keywords: Alcoholic hepatitis, Alcohol Metabolism Liver Transplantation, Liver Biopsy, MELD, Corticosteroids, N-Acetylcysteine (NAC), Maddrey's Discriminant Function (DF), Future Directions, Treatments of alcoholic hepatitis.

1. INTRODUCTION

Alcoholic Hepatitis (AH) represents the most severe syndrome of all alcohol-induced liver pathologies, characterised by a sudden onset of jaundice and clinical signs of hepatic decompensation along with an intense systemic inflammatory response and high short-term mortality. AH is a distinct clinical syndrome caused by chronic alcohol abuse and carries a particularly poor prognosis, with 28-day mortality ranging from 30% to 50%. Although AH is an acute condition, nearly 50% of patients with AH have established cirrhosis at the time of clinical presentation.[1]

Alcohol consumption was identified as a risk factor for liver disease centuries ago when Laennec documented a high prevalence of cirrhosis among heavy drinkers.

1. Modern epidemiological data from many societies confirm a strong correlation between death attributable to cirrhosis and per capita consumption of alcohol.

2. No particular quantity of alcohol consumption predictably results in alcoholic liver disease (ALD).[2]

Excessive alcohol consumption can cause a range of injuries to the liver, from negligible to fatty infiltration to cirrhosis over the course of several years. Sustained, excessive alcohol use can cause inflammatory changes in the liver, leading to more serious damage known as alcoholic steatohepatitis, or Alcoholic Hepatitis.[3] A subset of these patients will eventually develop severe alcoholic hepatitis, which carries a much more direct short-term prognosis. Depending on the degree of inflammation and damage, these conditions may lead to fibrosis and eventually cirrhosis and liver failure.[4]

Patients with severe AH are at particularly increased risk for infection for several reasons. First, the immune function of circulating innate immune cells is impaired, as multiple studies have identified decreased phagocytic activity, oxidative burst, and proliferation in severe AH. Second immunosuppression with corticosteroids impacts infection risk, as shown in a sub-analysis of the STOP Alcoholic Hepatitis trial, where circulating bacterial DNA detected at enrolment was associated with the development of early infections (within 7 days of commencing treatment) only among patients who received prednisolone.[5] The source and the type of infection also change during the disease course. In an early study of AH, spontaneous bacterial peritonitis and spontaneous bacteremia were leading infections at initial presentation, whereas respiratory infections were the most common infections after exposure to corticosteroids.[6][7]

2. Epidemiology

In Worldwide

The global epidemiology of alcoholic hepatitis, a severe form of alcohol-related liver disease (ARLD), reflects a concerning public health burden that varies by region, gender, and socioeconomic status.[8]

Prevalence:

Alcoholic hepatitis (AH) represents a significant public health burden. In 2007, approximately 56,000 patients were hospitalized with AH across the United States. The mean age of those hospitalized was 53 years; nearly 75% of these patients were male. Forty-four percent of all deaths from liver disease in 2003 were attributable to alcohol-induced disease. One study conducted in Denmark from 1999-2008 found the 28 day mortality rate for patients with alcoholic hepatitis to be 14-24%, with 5year mortality rate of 56%.[9]

Globally, alcohol-related liver disease (ARLD)—which includes alcoholic hepatitis—is estimated to have a prevalence of about 4.8% across populations. This figure varies significantly by region, gender, and drinking patterns. For instance, prevalence is notably higher among males (2.9%) compared to females (0.5%).[10] Among ethnic groups, Caucasians showed the highest representation in ARLD cases, and chronic heavy drinking (often over 20 years with an average intake of 146.6 g/day) was a major contributing factor. The incidence rate globally is around 0.208 per 1,000 person-years, and the overall mortality for ARLD is approximately 23.9%, with liver-related deaths accounting for 21.6%.[11] Interestingly, regions like Central Asia and Eastern Europe have seen the sharpest increases in incidence and mortality over the past 30 years, likely due to higher alcohol consumption and limited access to healthcare resources.[12][13]

Alcohol-related liver disease (ARLD), which includes alcoholic hepatitis, has a global prevalence of approximately 4.8%. The condition is significantly more common in males (2.9%) than in females (0.5%).[14]

Geographic Variation:

The highest age-standardized incidence and mortality rates are reported in Central Asia and Eastern Europe, where alcohol consumption is particularly high.[15]

Risk Factors:

Chronic heavy drinking (average intake ~146.6 g/day), smoking (59.5% of ARLD patients), and co-infection with hepatitis viruses (18.7%) are major contributors.[16]

Outcomes:

The overall mortality for ARLD is around 23.9%, with liver-related mortality at 21.6%. Alcoholic cirrhosis and alcoholic hepatitis are among the most severe outcomes.

Trends:

Despite some improvements in healthcare access, the burden of alcoholic hepatitis has not significantly declined over the past 30 years globally. In fact, some regions have seen increases due to rising alcohol use and limited preventive strategies.[17]

In India:

In India, the epidemiology of alcoholic hepatitis reflects a growing public health concern, shaped by shifting cultural norms, urbanisation, and increased alcohol availability.[18]

Rising Burden:

Alcoholic liver disease (ALD), including alcoholic hepatitis, is becoming a leading cause of chronic liver disease in India. This trend is driven by increasing alcohol consumption, especially among younger adults and in urban areas.[19]

Demographics:

ALD is more prevalent in males, but recent data suggest a rising incidence among women, likely due to changing social behaviors and reduced stigma around alcohol use.

Mortality And Morbidity:

India contributes to 18.3% of global liver disease–related deaths, with ALD playing a significant role. Alcoholic hepatitis often presents late, with complications like cirrhosis, ascites, and hepatic encephalopathy.[20]

Co-Factors:

Co-infection with hepatitis B or C, poor nutrition, and delayed diagnosis exacerbate disease progression and outcomes.

Data Limitations:

Epidemiological data in India are fragmented due to inconsistent reporting, lack of centralized registries, and underdiagnosis, especially in rural areas.[21]

3. Symptoms Of Alcoholic Hepatitis

Alcoholic hepatitis is a severe liver condition caused by excessive alcohol consumption. Its symptoms can range from mild to severe and may develop suddenly or over time. Common symptoms include:

- **Fatigue and Weakness**: Feeling unusually tired or weak.
- **Loss of Appetite and Weight Loss**: Decreased desire to eat and un-intended weight loss.
- **Nausea and Vomiting**: Feeling nauseous and possibly vomiting.
- **Abdominal Pain**: Discomfort or pain in the upper right side of the abdomen.
- **Jaundice**: Yellowing of the skin and eyes.
- **Fever**: Often low-grade.
- **Ascites**: Fluid buildup in the abdomen, causing swelling.
- **Spider Angiomas**: Small, spider-like blood vessels visible under the skin.
- **Easy Bruising or Bleeding**: Increased tendency to bruise or bleed.
- **Confusion or Mental Changes**: Altered thinking or consciousness, possibly due to hepatic encephalopathy.
- **Palmar Erythema**: Redness of the palms of the hands.
- **Hepatic Encephalopathy**: A condition that affects brain function due to liver failure.[22][23]



Figure 1. Various symptoms.

4. Causes of Alcoholic Hepatitis

The primary cause of AH is chronic heavy drinking. However, not all heavy drinkers develop AH

- **Alcohol Metabolism**: The liver metabolises alcohol into acetaldehyde, a toxic compound that can damage liver cells. This process generates free radicals and pro-inflammatory cytokines, leading to liver inflammation and injury. [24]
- **Genetic Factors**: Genetic predispositions can influence how individuals metabolise alcohol and their susceptibility to liver damage. Certain genetic variations may increase the risk of developing AH.
- **Gender Differences**: Women are more susceptible to alcohol-related liver disease than men, possibly due to differences in alcohol metabolism and hormonal factors.[25]
- **Obesity and Smoking**: Obesity and smoking can exacerbate liver damage in individuals who consume alcohol, increasing the risk of developing AH.
- **Nutritional Deficiencies**: Heavy drinking often leads to poor nutrition, which can impair liver function and contribute to the development of AH.[26]

5. Pathogenesis

Pathogenesis of alcoholic hepatitis is complex interaction of

1. Alcohol Metabolism
2. Oxidative Stress
3. Gut-Liver Axis
4. Immune System Activation
5. Inflammation
6. Liver Cell Death
7. Impaired Regeneration
8. Progression To Cirrhosis.[27][28]

1. Alcohol Metabolism:

Alcohol metabolism is the enzymatic breakdown of ethanol in the liver, primarily by alcohol dehydrogenase (ADH) and cytochrome P450 2E1 (CYP2E1), producing toxic metabolites like acetaldehyde and reactive oxygen species (ROS), which contribute to inflammation, oxidative stress, and hepatocellular injury seen in alcoholic hepatitis.[29]

2. Oxidative Stress:

Oxidative stress in alcoholic hepatitis refers to the imbalance between the production of reactive oxygen species (ROS) and the liver's antioxidant defences, leading to cellular and tissue damage.

In the context of alcoholic hepatitis, chronic alcohol metabolism, especially through the CYP2E1 enzyme pathway, generates excess ROS. These reactive molecules damage lipids, proteins, and DNA in liver cells, contributing to inflammation, necrosis, and fibrosis characteristic of the disease.[30]

3. Gut-Liver Axis:

The gut-liver axis in alcoholic hepatitis is the connection between the gut and liver, where alcohol-induced gut damage allows toxins to enter the liver, triggering inflammation and liver injury.[31]

4. Immune System Activation:

Immune system activation in alcoholic hepatitis is the excessive immune response triggered by alcohol and gut-derived toxins, leading to liver inflammation and injury.[32]

5. Inflammation:

Inflammation in alcoholic hepatitis is the liver's immune response to alcohol-induced injury, marked by immune cell infiltration and release of pro-inflammatory cytokines.[33]

6. Liver Cell Death:

Liver cell death in alcoholic hepatitis is the alcohol-driven loss of hepatocytes through apoptosis and necrosis, releasing danger signals that worsen liver inflammation and damage.[34]

7. Impaired Regeneration:

Impaired regeneration in alcoholic hepatitis is the reduced ability of the liver to repair and replace damaged cells due to ongoing inflammation and alcohol toxicity.[35]

8. Progression To Cirrhosis:

Progression to cirrhosis in alcoholic hepatitis is the gradual development of permanent liver scarring due to sustained inflammation and cell damage from chronic alcohol use.[36]

6. Diagnosis

Diagnosing alcoholic hepatitis involves a combination of clinical evaluation, laboratory tests, and sometimes imaging or biopsy.[37]

1. Clinical Assessment

History of alcohol use: Typically heavy consumption for more than 6 months.

Symptoms: Jaundice, fever, right upper quadrant pain, nausea, and fatigue.

Physical exam: May reveal hepatomegaly, ascites, or signs of chronic liver disease.[38]

2. Laboratory Tests

Liver enzymes: AST is typically elevated more than ALT, often in a ratio >2:1.
Bilirubin: Elevated, indicating impaired liver function.
INR and albumin: To assess synthetic liver function.
Complete blood count: May show anemia or leukocytosis.[39]

3. Imaging

Ultrasound: Helps assess liver size, texture, and the presence of ascites.
CT or MRI Scans: Provide detailed images to evaluate liver structure and detect complications.[40]

4. Liver Biopsy

Considered when diagnosis is uncertain or to rule out other liver pathologies. It shows characteristic features like ballooning degeneration, Mallory bodies, and neutrophilic infiltration.[41]

5. Non-invasive Biomarkers

ASH Test: Combines components of the FibroTest-ActiTest with AST levels to assess liver inflammation and fibrosis.

Carbohydrate-Deficient Transferrin (CDT): Reflects chronic alcohol consumption and can aid in distinguishing AH from other liver diseases.[42]

6. Special Scoring

1. Maddrey's Discriminant Function (DF)

Definition: A score used to predict short-term mortality and determine need for corticosteroid therapy in alcoholic hepatitis.
Formula: DF = 4.6 × (Patient's prothrombin time – Control prothrombin time) + Total bilirubin (mg/dL)
DF ≥ 32: Severe alcoholic hepatitis → high short-term mortality (~30–50% at 1 month). Consider corticosteroids.
DF < 32: Mild to moderate disease → supportive care usually sufficient.[43]

2. Model for End-Stage Liver Disease (MELD) Score

Definition: A prognostic model originally for cirrhosis but often used in AH to assess severity and transplant eligibility.
Formula:
MELD = 3.78 × ln[bilirubin] + 11.2 × ln[INR] + 9.57 × ln[creatinine] + 6.43
Higher score → worse prognosis.
MELD > 20 often indicates poor outcomes in AH.[44]

3. Lille Score

Definition: A score used to assess response to corticosteroid therapy after 7 days in patients with severe alcoholic hepatitis.
Variables: Age, Albumin (day 0), Bilirubin (day 0 and day 7), Creatinine, Prothrombin time.
Interpretation:
Lille score > 0.45:
Poor response to steroids → consider stopping therapy.
Lille score ≤ 0.45:
Continued steroid therapy may be beneficial.[45]

4. Glasgow Alcoholic Hepatitis Score (GAHS)

Definition: Assesses severity and guides therapy.
Variables: Age, WBC, Urea, INR, Bilirubin
Score ≥ 9:
Severe disease → steroids may be considered.
Score < 9:
Mild/moderate disease → supportive care.[46]

7. Prognostic Markers

A prognostic marker for alcoholic hepatitis is a measurable clinical or biochemical indicator used to predict the likely course or outcome of the disease. These markers help assess disease severity, guide treatment decisions, and estimate short- and long-term mortality risk.[47]

Abbreviations:

- MELD: model for end-stage liver disease
- INR: international normalized ratio
- BUN: blood urea nitrogen
- AKI: acute kidney injury
- WBC: white blood cells
- MDF: maddrey discriminant function
- AAH: alcohol-associated hepatitis
- PT: prothrombin time
- GAHS: glasgow alcoholic hepatitis score
- ABIC: age-bilirubin-INR-creatinine score.[48][49][50]

Marker / Score	Type	Components / Basis	Prognostic Significance
Maddrey Discriminant Function (MDF)	Clinical Score	PT, serum bilirubin	MDF ≥32 indicates severe disease; guides corticosteroid therapy
Model for End-Stage Liver Disease (MELD)	Composite Score	Bilirubin, INR, creatinine	MELD >20 suggests high short-term mortality
Glasgow Alcoholic Hepatitis Score (GAHS)	Composite Score	Age, WBC, urea, PT ratio, bilirubin	GAHS ≥9 predicts poor outcome; helps identify steroid responders
Lille Score	Dynamic Score	Age, albumin, bilirubin (day 0 & 7), creatinine, PT	Lille >0.45 = poor response to corticosteroids
ABIC Score	Composite Score	Age, bilirubin, INR, creatinine	Stratifies patients into low, intermediate, and high 90-day mortality risk
Neutrophil-to-Lymphocyte Ratio (NLR)	Hematologic Marker	Neutrophil count / lymphocyte count	Elevated NLR correlates with systemic inflammation and poor prognosis
Serum Keratin-18 (K18)	Apoptosis Marker	Hepatocyte apoptosis and necrosis fragments	High levels reflect severe hepatocyte injury
Soluble CD163 (sCD163)	Inflammatory Marker	Macrophage activation	Elevated in severe AAH; linked to hepatic inflammation
C-reactive Protein (CRP)	Inflammatory Marker	Acute-phase reactant	High CRP may predict poor steroid response

Alcoholic Hepatitis Histologic Score (AHHS)	Histologic Score	Fibrosis, bilirubinostasis, neutrophil infiltration, megamitochondria	Predicts 90-day mortality; biopsy-based

Table 1: prognostic markers

8. Biomarkers

Alcoholic hepatitis (AH) is a severe inflammatory condition of the liver caused by excessive alcohol intake, and identifying reliable biomarkers is crucial for diagnosis, prognosis, and treatment response.[51][52]

Biochemical and Hematological Markers

- AST/ALT ratio: Typically >2:1 in AH, due to mitochondrial damage and vitamin B6 deficiency.
- Total bilirubin: Elevated levels reflect impaired liver function.
- Prothrombin time (PT)/INR: Prolonged PT indicates reduced hepatic synthetic capacity.
- Albumin: Often decreased due to impaired protein synthesis.
- Gamma-glutamyltransferase (GGT) and alkaline phosphatase (ALP): Elevated in cholestatic injury.
- White blood cell count: Often elevated due to systemic inflammation.[53]

Emerging and Novel Biomarkers

- Keratin-18 (K18): A marker of hepatocyte apoptosis and necrosis.
- MicroRNAs (e.g., miR-122): Reflect liver-specific injury and inflammation.
- Sphingolipids: Especially C16-Sphinganine-1-phosphate (S1P), which is elevated in AH.
- Prostaglandin E2 (PGE2): Found to be decreased in AH. The PGE2/S1P ratio has shown high diagnostic accuracy in distinguishing AH from decompensated cirrhosis.
- Ursodeoxycholic acid: Lower levels correlate with higher mortality risk and disease severity.[54]

9. Pharmacological Treatment

Treatment for alcoholic hepatitis focuses on halting liver damage, managing symptoms, and supporting recovery. The main goal of pharmacological treatment is to reduce liver inflammation and improve survival, especially in severe cases.[55][56]

1) Propylthiouracil:

Propylthiouracil (PTU) decreases the hypermetabolic state induced by alcohol and inhibits oxidative stress. Previous studies showed conflicting results of PTU in the treatment of alcoholic hepatitis. In a recent systemic review, PTU failed to show the effect in the treatment of alcoholic liver disease.[57]

2) Corticosteroids (Prednisolone):

Prednisolone 40 mg/day orally for 28 days is the first-line treatment for patients with severe alcoholic hepatitis (Maddrey's Discriminant Function ≥32). Corticosteroids help reduce liver inflammation and improve short-term survival. The response is evaluated after 7 days using the Lille score to determine whether to continue therapy.[58]

3) Pentoxifylline:

Previously used to inhibit inflammatory cytokines, but current evidence does not support its routine use due to lack of significant survival benefit.[59]

4) Nutritional Support:

Each nutrient plays a distinct role in supporting liver recovery, especially in conditions like alcoholic hepatitis where liver function is compromised.[60]

Thiamine (Vitamin B1)

- Essential for carbohydrate metabolism and energy production.
- Prevents Wernicke's encephalopathy, a neurological complication common in alcohol misuse.

Folate & Vitamin B12

- Support DNA synthesis and repair, crucial for regenerating liver cells.
- Help reduce homocysteine levels, which can damage blood vessels and liver tissue.

Zinc

- Aids in ammonia detoxification via the urea cycle.
- Supports immune function and reduces oxidative stress in liver cells.

Magnesium

- Involved in enzyme activation and stabilizing cell membranes.
- Deficiency can worsen inflammation and insulin resistance, both harmful to liver health.

Phosphate

- Vital for ATP production, the energy currency of cells.
- Supports cell membrane integrity and intracellular signaling.

Protein

- Provides amino acids for liver tissue repair and enzyme synthesis.
- Helps maintain oncotic pressure and prevent muscle wasting.

Complex Carbohydrates

- Offer a steady energy source without spiking blood sugar.
- Reduce the liver's burden of metabolizing excess fats.

Healthy Fats (e.g., omega-3s)

- Exhibit anti-inflammatory effects.
- May help reduce hepatic steatosis (fat accumulation in the liver).[61][62]

5) Liver Transplantation for Alcoholic Hepatitis:

1. Indications

Liver transplantation is considered for patients with severe alcoholic hepatitis who: Do not respond to medical therapy (e.g., corticosteroids).Have life-threatening liver failure Meet other transplant criteria (medical, psychological, social)

Traditionally, most centers required 6 months of abstinence ("6-month rule") before listing for transplant. However, this rule is being reconsidered, especially for severe AH patients who have poor prognosis and limited treatment options.

2. Selection Criteria

Strict selection process to identify candidates with: Good psychosocial support. No other active substance abuse. Commitment to abstinence post-transplant. Absence of severe psychiatric disorders. First episode of liver decompensation (some centers prioritize this)

Recent studies (e.g., Mathurin et al., NEJM 2011) have shown early liver transplantation without the 6-month abstinence requirement can improve survival in highly selected patients with severe AH.

3. Outcomes

Survival rates post-transplant for AH patients are comparable to those transplanted for other indications. Recidivism rates (return to harmful drinking) are variable but relatively low when careful psychosocial screening is done. Transplant improves quality of life and reduces mortality in selected patients with severe AH unresponsive to medical treatment.

4. Controversies and Challenges

Ethical concerns about allocating scarce donor organs to patients with alcohol-related disease. Balancing the risk of relapse versus potential survival benefit. Variability in transplant center policies worldwide regarding early transplantation for AH.[63][64]

6) Antioxidants in Alcoholic Hepatitis:

Alcoholic hepatitis (AH) involves oxidative stress and inflammation due to alcohol metabolism, which produces reactive oxygen species (ROS). Antioxidants aim to reduce oxidative damage and improve liver function.[65]

1.N-Acetylcysteine (NAC)

- ✓ NAC replenishes glutathione, a major intracellular antioxidant, reducing oxidative stress and liver injury.
- ✓ Often used in combination with corticosteroids.

- ✓ Clinical trials suggest NAC plus prednisolone may improve short-term survival and reduce complications like infections and renal failure.

2. S-Adenosylmethionine (SAMe)

- ✓ SAMe is a methyl donor involved in glutathione synthesis.
- ✓ Some studies suggest it may improve liver function and reduce oxidative stress in alcoholic liver disease, but evidence in AH is limited.

3. Vitamin E

- ✓ A lipid-soluble antioxidant thought to reduce oxidative injury.[66][67]

7) Amino Acid Therapy in Alcoholic Hepatitis:

- ✓ Alcoholic hepatitis is commonly associated with malnutrition and muscle wasting, which worsen patient outcomes. Amino acid therapy, particularly supplementation with branched-chain amino acids (BCAAs), plays an important role in nutritional management.
- ✓ BCAAs (leucine, isoleucine, valine) help improve protein synthesis, reduce muscle catabolism, and support liver regeneration.
- ✓ Supplementation may improve nitrogen balance, reduce complications like hepatic encephalopathy, and enhance overall survival in patients with alcoholic liver disease.
- ✓ Guidelines recommend adequate protein intake (1.2–1.5 g/kg/day) and consider BCAA-enriched formulas especially in cases of advanced liver disease or intolerance to normal protein intake.[68]

10. Liver Biopsy

A liver biopsy is a simple bedside procedure. A healthcare provider uses a hollow needle to draw a tiny tissue sample from your liver. A pathologist will study it under a microscope. This sample can reveal crucial information about your liver condition.[69]

A liver biopsy is a minor procedure to take a tiny tissue sample from your liver through a hollow needle. Healthcare providers do this in a few different ways, depending on your condition. After the procedure, a pathologist analyzes the tissue sample in a lab to help diagnose and stage various liver diseases.[70]

Relationship Between Different Types Of Biomarkers And Their Roles In Guiding Treatment Decisions:[71][72]

Biomarker Type	Function	Example	Impact on Treatment
Diagnostic Biomarkers	Identify presence of disease	PSA (Prostate-Specific Antigen)	Early detection of prostate cancer; guides need for biopsy or further testing
Prognostic Biomarkers	Predict disease outcome regardless of treatment	HER2 in breast cancer	Indicates aggressive tumor; helps assess risk and plan monitoring
Predictive Biomarkers	Predict response to a specific therapy	EGFR mutation in NSCLC	Guides use of EGFR inhibitors like gefitinib or erlotinib

Pharmacodynamic Biomarkers	Indicate biological response to a treatment	HbA1c in diabetes	Monitors effectiveness of antidiabetic therapy
Safety Biomarkers	Signal potential toxicity or adverse effects	Troponin levels during chemotherapy	Detects early cardiac toxicity; may lead to dose adjustment or therapy switch
Monitoring Biomarkers	Track disease progression or recurrence	CA-125 in ovarian cancer	Used to monitor treatment response and detect relapse

11. Future Directions

Targeted Therapies: Current treatments like corticosteroids have limited efficacy and safety concerns. Future strategies are focusing on targeting inflammatory pathways, oxidative stress, and gut-liver axis dysfunction. Agents like IL-22, FXR agonists, and anti-TNF therapies are under investigation.[73]

Biomarker Development: There's a growing need for noninvasive biomarkers to predict disease severity, treatment response, and long-term outcomes. These would reduce reliance on liver biopsies and improve patient stratification.[74]

Early Liver Transplantation (eLT): While controversial, eLT is gaining traction for select patients with severe AH who are non-responsive to medical therapy. Future efforts aim to standardize selection criteria and improve access.[75]

Integrated Care Models: Multidisciplinary approaches that combine hepatology, addiction medicine, nutrition, and mental health are being emphasized to address both alcohol use disorder and liver injury simultaneously.[76]

Clinical Trial Innovation: There's a push to overcome challenges in trial design, such as patient heterogeneity and ethical concerns, to accelerate drug development in AH.

Microbiome Modulation: Gut dysbiosis plays a key role in AH pathogenesis. Future therapies may include probiotics, prebiotics, or fecal microbiota transplantation to restore gut-liver homeostasis.[77]

12. Conclusion

Alcoholic hepatitis remains a major clinical challenge due to its high short-term mortality and limited therapeutic options. Prognostic models are essential tools for identifying patients who may benefit from aggressive interventions. While corticosteroids offer modest survival benefits in severe cases, the need for novel therapies is pressing. Future research should focus on refining prognostic tools, exploring regenerative therapies, and improving access to liver transplantation for eligible patients. Sustained alcohol abstinence remains the cornerstone of long-term survival.

Acknowledgments:

The authors are grateful to the management and principal of Sankaralingam Bhuvaneshwari College of Pharmacy, Sivakasi, for providing the necessary facilities and encouragement to carry out this work. We sincerely thank the faculty members of the Department of Pharmaceutics for their valuable guidance and support throughout the preparation of this review article. The authors also extend their heartfelt appreciation to colleagues, friends, and family members for their constant motivation and cooperation.

REFERENCE:

1. Lefkowitch JH. Morphology of alcoholic liver disease. Clinical Liver Disease. 2005;9(1):37-53.
2. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. The Lancet. 1995;346(8981):987-990.
3. Mookerjee RP, Stadlbauer V, Lidder S, Wright GA, Hodges SJ, Davies NA, et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology. 2007;46(3):831-840.
4. Vergis N, Atkinson SR, Knapp S, Patel VP, Shetty S, Alonso C, et al. In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with high circulating levels of bacterial DNA. Gastroenterology. 2017;152(5):1068-1077.e4.
5. Kasper P, Lang S, Steffen HM, Demir M. Management of alcoholic hepatitis: a clinical perspective. Liver International. 2023;43(9):1945-1957. doi:10.1111/liv.15701.
6. Basra S, Anand BS. Definition, epidemiology and magnitude of alcoholic hepatitis. World Journal of Hepatology. 2011;3(5):108-113.
7. Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. Seminars in Liver Disease. 2004;24(3):217-232.
8. Becker U, Deis A, Sørensen TI, Grønbaek M, Borch-Johnsen K, Müller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996;23(5):1025-1029.
9. Jewell J, Sheron N. Trends in European liver death rates: implications for alcohol policy. Clinical Medicine. 2010;10(3):259-263.
10. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology. 2002;35(3):635-638.
11. World Health Organization. Global status report on alcohol and health. Geneva: World Health Organization; 2011.
12. Yoon YH, Yi HY. Liver cirrhosis mortality in the United States, 1970–2007. Bethesda (MD): National Institute on Alcohol Abuse and Alcoholism; 2010.
13. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. The New England Journal of Medicine. 2009;360(26):2758-2769.
14. Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG Clinical Guideline: Alcohol-associated liver disease. American Journal of Gastroenterology. 2018;113(2):175-194.
15. McClain CJ, Song Z, Barve SS, Hill DB, Deaciuc I. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. American Journal of Physiology - Gastrointestinal and Liver Physiology. 2004;287(3):G497-G502.
16. Ceccanti M, Attili A, Balducci G, Attilia F, Giacomelli S, Rotondo C, et al. Acute alcoholic hepatitis. Journal of Clinical Gastroenterology. 2006;40(9):833-841.
17. Bjarnason I, Peters TJ, Wise RJ. The leaky gut of alcoholism: possible route of entry for toxic compounds. The Lancet. 1984;1(8370):179-182.
18. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011;141(5):1572-1585.
19. Cederbaum AI. Alcohol metabolism. Clinical Liver Disease. 2012;16(4):667-685.

20. Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, et al. The gut–liver axis and the intersection with the microbiome. Nature Reviews Gastroenterology and Hepatology. 2018;15(7):397-411.
21. Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nature Reviews Gastroenterology and Hepatology. 2015;12(7):387-400.
22. Gao B, Ahmad MF, Nagy LE, Tsukamoto H. Inflammation in alcoholic liver disease. Alcoholism: Clinical and Experimental Research. 2019;43(4):763-773.
23. Tsukamoto H, Machida K, Dynnyk A, Mkrtchyan H. “Second hit” models of alcoholic liver disease. Seminars in Liver Disease. 2009;29(2):178-187.
24. Sancho-Bru P, Altamirano J, Rodrigo-Torres D, Coll M, Millán C, Lozano JJ, et al. Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology. 2012;55(6):1931-1941.
25. Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020;71(1):306-333.
26. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41(2):353-358.
27. Forrest EH, Evans CDJ, Stewart S, Phillips M, Oo YH, McDonald D, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow Alcoholic Hepatitis Score. Gut. 2005;54(8):1174-1179.
28. Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Thabut D, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45(6):1348-1354.
29. Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. The New England Journal of Medicine. 2011;365(19):1790-1800.
30. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of alcohol-related liver disease. Journal of Hepatology. 2018;69(1):154-181.
31. Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury. Gastroenterology. 2008;134(6):1641-1654.
32. Osna NA, Donohue TM, Kharbanda KK. Alcoholic liver disease: pathogenesis and current management. Alcohol Research. 2017;38(2):147-161.
33. Crabb DW, Bataller R, Chalasani NP, et al. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology. 2016;150(4):785-790.
34. Arab JP, Arrese M, Singal AK. Diagnosis of alcohol-associated hepatitis: when is liver biopsy required? Clinical Liver Disease. 2021;25(3):571-584.
35. Scotto J, Opolon P, Eteve J, et al. Liver biopsy and prognosis in acute liver failure. Gut. 1973;14(11):927-933.
36. McCullough AJ, O’Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Gastroenterology. 1998;93(11):2022-2036.
37. Liangpunsakul S. Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States. Journal of Clinical Gastroenterology. 2011;45(8):714-719.
38. Forrest EH, Evans CDJ, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation of the Glasgow Alcoholic Hepatitis Score. Gut. 2005;54(8):1174-1179.
39. Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45(6):1348-1354.
40. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47(4):1363-1370.
41. Arrese M, Eguchi A, Feldstein AE. Circulating microRNAs: emerging biomarkers of liver disease. Seminars in Liver Disease. 2015;35(1):43-54.

42. Petrasek J, Iracheta-Vellve A, Saha B, Satishchandran A, Kodys K, Fitzgerald KA, et al. Metabolic danger signals, uric acid and ATP, mediate inflammatory cross-talk between hepatocytes and immune cells in alcoholic liver disease. Journal of Leukocyte Biology. 2015;98(2):249-256.

43. Mathurin P, Bataller R. Trends in the management and burden of alcoholic liver disease. Journal of Hepatology. 2015;62(1 Suppl):S38-S46.

44. Mathurin P, Mendenhall C, Carithers RL Jr, et al. Corticosteroids improve short term survival in patients with severe alcoholic hepatitis: individual data analysis of randomized placebo-controlled trials. Journal of Hepatology. 2002;36(4):480-487.

45. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119(6):1637-1643.

46. Stickel F, Hoehn B, Schuppan D, Seitz HK. Nutritional therapy in alcoholic liver disease. Alimentary Pharmacology and Therapeutics. 2003;18(4):357-373.

47. Suter PM. Alcohol: its role in health and nutrition. In: Bowman BA, Russell RM, editors. Present Knowledge in Nutrition. 3rd ed. Washington (DC): International Life Sciences Institute Press; 2001. p. 497-507.

48. Lieber CS. Relationships between nutrition, alcohol use, and liver disease. Alcohol Research and Health. 2003;27(3):220-231.

49. Addolorato G, Bataller R, Burra P, et al. Liver transplantation for alcoholic liver disease: current status and controversies. Transplantation. 2016;100(5):981-987.

50. Arteel GE. Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology. 2003;124(3):778-790.

51. Kalyanaraman B. Teaching the basics of redox biology to medical and graduate students: oxidants, antioxidants and disease mechanisms. Redox Biology. 2013;1:244-257.

52. Meijer AJ. Amino acids as regulators and components of non-proteinogenic pathways. Journal of Nutrition. 2003;133(6 Suppl 1):2057S-2062S.

53. Tedesco L, Corsetti G, Ruocco C, et al. A specific amino acid formula prevents alcoholic liver disease in rodents. American Journal of Physiology - Gastrointestinal and Liver Physiology. 2018;314(6):G566-G574.

54. Nalbantoglu I, Brunt EM. Role of liver biopsy in nonalcoholic fatty liver disease. World Journal of Gastroenterology. 2014;20(27):9026-9037.

55. Kobyliak N, Dynnyk O, Abenavoli L. The role of liver biopsy to assess alcoholic liver disease. Reviews on Recent Clinical Trials. 2016;11(3):175-179.

56. Campbell MS, Reddy KR. The evolving role of liver biopsy. Alimentary Pharmacology and Therapeutics. 2004;20(5):573-578.

57. Horhat A, Fischer P, Nicoara-Farcau O, Rusu I, Morar C, Bumbu A, et al. Enhanced diagnosis and prognosis of severe alcoholic hepatitis using novel metabolomic biomarkers. Alcohol and Alcoholism. 2023;58(4):366-374.

58. Ramírez-Mejía MM, Morales-Galicia AE, Méndez-Sánchez N. Prognostic challenges in alcoholic hepatitis: from scoring systems to clinical predictors. World Journal of Hepatology. 2025;17(5):105769.

59. Dugum MF, McCullough AJ. Acute alcoholic hepatitis: the clinical aspects. Clinical Liver Disease. 2016;20(3):499-508.

60. Torok NJ. Update on alcoholic hepatitis. Biomolecules. 2015;5(4):2978-2986.

61. Thursz M, Forrest E, Ryder S, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine. 2015;372(17):1619-1628.

62. European Association for the Study of the Liver. EASL clinical practical guidelines: management of alcoholic liver disease. Journal of Hepatology. 2012;57(2):399-420.

63. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. New England Journal of Medicine. 2009;360(26):2758-2769.

64. Basra S, Anand BS. Definition, epidemiology and magnitude of alcoholic hepatitis. World Journal of Hepatology. 2011;3(5):108-113.

65. Liangpunsakul S, Haber P, McCaughan GW. Alcoholic liver disease in Asia, Europe, and North America. Gastroenterology. 2016;150(8):1786-1797.

66. Parker R, Armengol S, Theocharidou E, et al. European survey on the management of alcoholic hepatitis. European Journal of Gastroenterology and Hepatology. 2017;29(6):652-659.

67. Gao B, Xu MJ, Bertola A, Wang H, Zhou Z, Liangpunsakul S. Animal models of alcoholic liver disease: pathogenesis and clinical relevance. Gene Expression. 2017;17(3):173-186.

68. Orman ES, Odena G, Bataller R. Alcoholic liver disease: pathogenesis, management, and novel targets for therapy. Journal of Gastroenterology and Hepatology. 2013;28(Suppl 1):77-84.

69. Singal AK, Shah VH. Current trials and novel therapeutic targets for alcoholic hepatitis. Journal of Hepatology. 2019;70(2):305-313.

70. Singal AK, Kamath PS, Gores GJ, Shah VH. Alcoholic hepatitis: current challenges and future directions. Clinical Gastroenterology and Hepatology. 2014;12(4):555-564.

71. Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020;71(1):306-333.

72. Altamirano J, Bataller R. Alcoholic liver disease: pathogenesis and new targets for therapy. Nature Reviews Gastroenterology and Hepatology. 2011;8(9):491-501.

73. Stickel F, Moreno C, Hampe J, Morgan MY. The genetics of alcohol dependence and alcohol-related liver disease. Journal of Hepatology. 2017;66(1):195-211.

74. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011;141(5):1572-1585.

75. Louvet A, Labreuche J, Artru F, et al. Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study. Hepatology. 2017;66(5):1464-1473.

76. Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG clinical guideline: alcoholic liver disease. American Journal of Gastroenterology. 2018;113(2):175-194.

77. Louvet A, Mathurin P. Alcoholic liver disease: mechanisms of injury and targeted treatment. Nature Reviews Gastroenterology and Hepatology. 2015;12(4):231-242.